IN2012DN00857A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00857A
IN2012DN00857A IN857DEN2012A IN2012DN00857A IN 2012DN00857 A IN2012DN00857 A IN 2012DN00857A IN 857DEN2012 A IN857DEN2012 A IN 857DEN2012A IN 2012DN00857 A IN2012DN00857 A IN 2012DN00857A
Authority
IN
India
Prior art keywords
pth
excellent safety
drug
achievement
inhibiting
Prior art date
Application number
Inventor
Shinichiro Shirae
Yasuo Nakamura
Yuiko Masunaga
Yoshihide Nozaki
Nobuyuki Kobayashi
Tatsuhiko Kuroda
Hiroki Kato
Masashi Serada
Kazuyoshi Hori
Original Assignee
Asahi Kasei Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43732444&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN00857(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Asahi Kasei Pharma Corp filed Critical Asahi Kasei Pharma Corp
Publication of IN2012DN00857A publication Critical patent/IN2012DN00857A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

To provide a method of treating osteoporosis by PTH that has excellent safety and high efficacy. To provide a method for inhibiting/preventing bone fractures by PTH that has excellent safety. And to provide a drug to do this. [Means of Achievement] A drug containing PTH as the active ingredient, characterized in that a unit dose of PTH of 100 to 200 units is administered weekly in the above method.
IN857DEN2012 2009-09-09 2010-09-08 IN2012DN00857A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009208039 2009-09-09
PCT/JP2010/065379 WO2011030774A1 (en) 2009-09-09 2010-09-08 Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units

Publications (1)

Publication Number Publication Date
IN2012DN00857A true IN2012DN00857A (en) 2015-07-10

Family

ID=43732444

Family Applications (1)

Application Number Title Priority Date Filing Date
IN857DEN2012 IN2012DN00857A (en) 2009-09-09 2010-09-08

Country Status (16)

Country Link
US (3) US20120252729A1 (en)
EP (3) EP2476429B1 (en)
JP (13) JPWO2011030774A1 (en)
KR (8) KR20190095552A (en)
CN (2) CN102470164B (en)
AU (1) AU2010293488B2 (en)
BR (1) BR112012003511A2 (en)
CA (1) CA2772656A1 (en)
ES (3) ES2663322T3 (en)
IL (1) IL217854A (en)
IN (1) IN2012DN00857A (en)
MX (1) MX335951B (en)
NZ (2) NZ598370A (en)
RU (1) RU2564894C2 (en)
WO (1) WO2011030774A1 (en)
ZA (1) ZA201201720B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101686271B1 (en) * 2009-11-18 2016-12-13 아사히 가세이 파마 가부시키가이샤 Preventive and/or therapeutic and/or aggravation suppressing agent for human arthritis deformans
JP6235219B2 (en) * 2013-03-21 2017-11-22 旭化成ファーマ株式会社 Bone fusion promoter after spinal interbody fusion
US10394953B2 (en) 2015-07-17 2019-08-27 Facebook, Inc. Meme detection in digital chatter analysis
US20190381341A1 (en) * 2017-02-01 2019-12-19 The Johns Hopkins University Parathyroid hormone and regeneration of degenerative discs disease
US20200289621A1 (en) * 2017-09-22 2020-09-17 Asahi Kasei Pharma Corporation Teriparatide-containing liquid pharmaceutical composition having excellent stability
JP2019060866A (en) * 2017-09-22 2019-04-18 旭化成ファーマ株式会社 Method for predicting biokinetics of liquid pharmaceutical composition
CA3075984C (en) * 2017-09-22 2024-10-01 Asahi Kasei Pharma Corporation Teriparatide-containing liquid pharmaceutical composition having excellent pharmacokinetics and/or safety
ES3009869T3 (en) 2018-10-29 2025-03-31 Asahi Kasei Pharma Corp An improved teriparatide dosage regimen for use in preventing or treating osteoporosis characterized by administering teriparatide or salt thereof twice a week
KR102920552B1 (en) * 2024-01-03 2026-01-30 김도영 Nanoscale manufacturing method for calcium carbonate and magnesium carbonate and osteoporosis prevention treatment manufactured using the method

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2505812B2 (en) 1987-07-10 1996-06-12 旭化成工業株式会社 Freeze-dried composition of h-PTH (1-34)
JP2662842B2 (en) 1991-12-09 1997-10-15 旭化成工業株式会社 Parathyroid hormone stabilizing composition
JPH0873376A (en) 1994-09-07 1996-03-19 Asahi Chem Ind Co Ltd Therapeutic agent for osteoporosis
SE9702401D0 (en) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
ZA9811127B (en) * 1997-12-09 2000-07-11 Lilly Co Eli Stabilized teriparatide solutions.
DZ2873A1 (en) * 1998-08-19 2003-12-15 Lilly Co Eli Method for increasing bone hardness and stiffness.
US6756480B2 (en) * 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
NZ523457A (en) 2000-06-30 2004-11-26 Daiichi Suntory Pharma Co Composition for stimulating bone formation comprising hPTH in which the acetic acid component is low enough for administration to the nasal mucosa
JP5042419B2 (en) * 2001-08-15 2012-10-03 旭化成ファーマ株式会社 Bone formation promoter and composition for promoting bone formation
JP4931306B2 (en) 2001-09-27 2012-05-16 旭化成ファーマ株式会社 Pharmaceutical complex that safely promotes bone formation
CN1816324A (en) * 2003-07-04 2006-08-09 尼克麦德丹麦公司 Parathyroid hormone (pth) containing pharmaceutical compositions for oral use
WO2005102381A1 (en) * 2004-04-26 2005-11-03 Ono Pharmaceutical Co., Ltd. Bone densifying agent characterized by use of cathepsin k inhibitor with pth
CA2567056A1 (en) * 2004-05-10 2005-12-08 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
JP2006241098A (en) * 2005-03-04 2006-09-14 Univ Kurume Preventive or therapeutic agent for bone loss
ES2443581T3 (en) * 2006-02-09 2014-02-19 Biomimetic Therapeutics, Llc Compositions and methods for bone treatment
DE102006043846A1 (en) * 2006-03-14 2007-09-20 Claudia Zours Spinal
AU2007225056A1 (en) * 2006-03-15 2007-09-20 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents to prevent or treat osteopenia
CN101274961A (en) * 2006-03-30 2008-10-01 天津医科大学 recombinant human parathyroid hormone-related protein
CN101125201A (en) * 2006-08-17 2008-02-20 石家庄欧意药业有限公司 Medicine composition for treating osteoporosis or preventing bone fracture caused by osteoporosis and its application
CN101307105B (en) * 2008-04-28 2012-08-29 中国药科大学 Human parathyroid hormone 1-34 peptide analogue capable of expressing in series and being released by synchronousacid hydrolysis, preparation method thereof and use

Also Published As

Publication number Publication date
BR112012003511A2 (en) 2019-09-24
JP6301524B2 (en) 2018-03-28
JP2015157854A (en) 2015-09-03
KR20170089018A (en) 2017-08-02
JP6043008B2 (en) 2016-12-14
JP2017105863A (en) 2017-06-15
JP6150846B2 (en) 2017-06-21
KR20140130754A (en) 2014-11-11
NZ598370A (en) 2014-04-30
AU2010293488A1 (en) 2012-03-29
KR20210040171A (en) 2021-04-12
US20140357560A1 (en) 2014-12-04
CA2772656A1 (en) 2011-03-17
RU2564894C2 (en) 2015-10-10
EP2476429B1 (en) 2018-03-07
KR20170089017A (en) 2017-08-02
US20140249084A1 (en) 2014-09-04
WO2011030774A1 (en) 2011-03-17
KR20190095552A (en) 2019-08-14
KR102335703B1 (en) 2021-12-07
EP2682125B1 (en) 2020-11-04
RU2012108635A (en) 2013-10-20
JP2015147813A (en) 2015-08-20
JP6198346B2 (en) 2017-09-20
JP2017105862A (en) 2017-06-15
EP2476429A1 (en) 2012-07-18
ES2662018T3 (en) 2018-04-05
EP2682125A1 (en) 2014-01-08
JP2017105859A (en) 2017-06-15
ES2843649T3 (en) 2021-07-20
CN102470164A (en) 2012-05-23
KR102424644B1 (en) 2022-07-25
EP2682124B1 (en) 2018-02-28
JP2017105861A (en) 2017-06-15
EP2682124A1 (en) 2014-01-08
ZA201201720B (en) 2012-11-28
JPWO2011030774A1 (en) 2013-02-07
JP6522715B2 (en) 2019-05-29
EP2476429A4 (en) 2013-02-27
JP2017061511A (en) 2017-03-30
NZ617397A (en) 2015-02-27
JP2016130261A (en) 2016-07-21
CN103893746A (en) 2014-07-02
ES2663322T3 (en) 2018-04-12
JP2019023234A (en) 2019-02-14
IL217854A0 (en) 2012-03-29
HK1168284A1 (en) 2012-12-28
JP2018024710A (en) 2018-02-15
JP2017105858A (en) 2017-06-15
CN102470164B (en) 2014-04-09
IL217854A (en) 2016-08-31
KR20150021590A (en) 2015-03-02
JP6275900B2 (en) 2018-02-07
KR20200115673A (en) 2020-10-07
JP2017105860A (en) 2017-06-15
US20120252729A1 (en) 2012-10-04
AU2010293488B2 (en) 2014-11-27
MX335951B (en) 2016-01-04
KR20120067336A (en) 2012-06-25
JP6274634B2 (en) 2018-02-07
MX2012002681A (en) 2012-04-19

Similar Documents

Publication Publication Date Title
IN2012DN00857A (en)
TN2012000143A1 (en) Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
MX363243B (en) Compositions and methods for treating cancer.
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
MX2013013809A (en) Expandable devices coated with a paclitaxel composition.
IN2015DN03219A (en)
MX2014008021A (en) Phenyl carbamate compounds for use in alleviating or treating pain and neuropathic pain.
PH12012500773A1 (en) A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof
SA113340494B1 (en) Composition for treating metabolic disorders
MX2013008074A (en) Combination.
DE502005005636D1 (en) Spirocyclische cyclohexan-derivate
MX341660B (en) Ghrelin receptor agonist for treatment of dyscrasia.
PH12012502093A1 (en) Composition for preventing or treating osteoporosis, and manufacturing method therefor
MX2013013808A (en) Expandable devices coated with a rapamycin composition.
IN2014DN09779A (en)
MX2014015096A (en) Crustacean feed.
MX2012003892A (en) Preventative agent and/or therapeutic agent and/or exacerbation-suppressing agent for human knee osteoarthritis.
WO2012011673A3 (en) Pharmaceutical composition including hesperetin as an active ingredient for promoting muscle cell differentiation or renewal
WO2011089531A3 (en) Effects of the association of vitamin k2 and vitamin d3 in the consolidation of a bone fracture
AU2014230304A8 (en) Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor
MX2014013491A (en) Methods of maintaining, treating or improving cognitive function.
WO2011136585A3 (en) Composition for treating bone disease comprising a glyceollin as an active ingredient
UA56460U (en) Method for treating traumatic injuries of peripheral nerve
UA53407U (en) Method for preventive maintenance and treatmens пepehaшиbahиe pregnancy
MX2012012712A (en) A pharmaceutical composition for use in treating or preventing either one or both of an inflammatory disease and an autoimmune disease.